08:50 AM EDT, 03/25/2026 (MT Newswires) -- LB Pharmaceuticals ( LBRX ) said Wednesday it has initiated a phase 3 trial evaluating LB-102 as a treatment for schizophrenia.

The randomized, double-blind, placebo-controlled trial is expected to enroll about 460 patients, who will be randomized to receive 50 mg or 100 mg of LB-102 or placebo for six weeks, the company said.

The primary endpoint will assess change in Positive and Negative Syndrome Scale total score at week 6, LB Pharmaceuticals ( LBRX ) said.

The company also said it plans to launch an open-label extension study enrolling about 900 patients to evaluate long-term safety and further assess effects on negative symptoms and cognitive performance.

Topline data from the trial is expected in H2 2027, the company said.

Shares of LB Pharmaceuticals ( LBRX ) were down 1.5% in Wednesday premarket activity.